Replies to post #104899 on Biotech Values

[rkrw]

The potential market size is huge.

[mcbio]

Re: ABT/Reata

Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys. In two Phase 2 clinical trials, bardoxolone significantly improved kidney function in patients with advanced CKD and Type 2 diabetes. CKD currently affects more than 50 million adults worldwide, and the number of patients is rapidly increasing throughout the world.

Are there any publicly traded small-cap biotechs working on drugs that increase eGFR?

[jq1234]

The first pivotal trial result must be positive for ABT to put that amount of upfront cash.

I looked at Reata website, here is what I found - I guess private company doesn't have to announce topline result quickly:

IRVING, TX - July 12, 2010 -- Reata Pharmaceuticals, Inc. ("Reata") has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.


This financing will fund the second of two pivotal trials of Reata's lead product candidate, bardoxolone methyl ("bardoxolone"), in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes. The primary endpoint of the ongoing first pivotal trial of bardoxolone was recently analyzed and the data are planned for presentation at a scientific meeting in November 2010.